Skip to main content

Gillheeney Gary S.'s Form 4 filing

Organogenesis Holdings Inc. (ORGO) · filed Dec 16, 2024

Accession no.
0001062993-24-020701
Filed
Dec 16, 2024
Trade date
Dec 13-16, 2024
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $206.4K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gillheeney Gary S.CIK 0001757373Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 13, 2024Class A Common StockSSaleDisposed−55,615$3.36F2−$186,866.43,044,779Direct
Dec 16, 2024Class A Common StockSSaleDisposed−5,585$3.49F3−$19,491.653,039,194Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.2806 to $3.50, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.36 to $3.5275, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)